About Tacalyx

Tacalyx researches and develops therapeutics targeting TACAs (tumor-associated carbohydrate antigens). These strongly tumor-specific structures are synthesized by cancer cells and contribute significantly to its virulence and metastasis. The recent possibility of synthesizing these complex structures allows the production of specific antibodies for the treatment of currently unsatisfactorily treatable cancers.

Press releases

25. September 2019

Tacalyx Raises €7 Million in Seed Funding to Generate First in Class Anti-TACA Antibodies for Cancer Treatment

Tacalyx, a biotech company focused on the discovery and development of novel anti-TACA (Tumor Associated Carbohydrate Antigens) cancer therapies, today announced that it has successfully secured €7 million in seed funding. The funding round involves a syndicate of leading European life science and technology investors co-led by Boehringer Ingelheim Venture Fund and Kurma Partners and joined by Idinvest Partners, High-Tech Gründerfonds (HTGF), coparion, and Creathor Ventures. Tacalyx, a spin-

Info & Contact

Peter Sondermann


Tacalyx GmbH
c/o Bayer CoLaborator (Gebäude S141)
Müllerstr. 178
13353 Berlin

In portfolio

02. Jul 2019



Dr. Frank Hensel

Principal / Authorized signatory